Fluticasone Furoate

證據等級: L5

預測適應症: 8 個

Fluticasone Furoate: From Allergic Rhinitis/Asthma to Atopic Eczema

One-Sentence Summary

Fluticasone furoate is a synthetic corticosteroid marketed internationally as an intranasal spray (allergic rhinitis) and, in combination with vilanterol, as an inhaled therapy for asthma/COPD. The TxGNN model predicts it may be effective for Atopic Eczema, with 10 relevant clinical trials and 2 publications currently available — though none directly test the furoate ester in this indication.

Quick Overview

Item	Content
Original Indication	Not on file in this evidence pack (0 SAHPRA licenses); internationally used as an intranasal/inhaled corticosteroid for allergic rhinitis and asthma
Predicted New Indication	Atopic Eczema
TxGNN Prediction Score	99.98%
Evidence Level	L3
South Africa Market Status	Not Marketed
Number of SAHPRA Registrations	0
Recommended Decision	Hold (Research Question stage)

Why is This Prediction Reasonable?

Detailed mechanism-of-action data for this specific product is currently a data gap. Based on known pharmacology, fluticasone furoate is a glucocorticoid receptor agonist belonging to the inhaled/intranasal corticosteroid class, whose efficacy in allergic rhinitis and asthma is well established internationally (including as the furoate component of Relvar/Breo Ellipta with vilanterol).

Corticosteroids act by suppressing T-cell activation and reducing pro-inflammatory cytokines (IL-4, IL-13, etc.) and mast cell activity — this is one of the standard mechanistic pathways used to treat atopic dermatitis/eczema. This provides a plausible pharmacological rationale for the TxGNN prediction.

However, the mechanistic link is indirect for this specific ester. Nearly all trials retrieved for atopic eczema use fluticasone propionate (not furoate) or tacrolimus as the active comparator, and no trial or publication in this evidence pack directly tests fluticasone furoate as monotherapy for atopic dermatitis. The prediction should therefore be read as class-level pharmacological plausibility rather than ester-specific clinical evidence.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT00690105	Phase 4	Completed	577	Tacrolimus 0.1% vs fluticasone 0.005% ointment for facial/neck atopic eczema; fluticasone used as active comparator
NCT00689832	Phase 4	Completed	487	Tacrolimus 0.03% vs fluticasone 0.005% ointment in children ≥2y with moderate–severe atopic dermatitis
NCT03742414	Phase 2	Active, not recruiting	398	Proactive skin-barrier cream + fluticasone propionate cream vs reactive therapy in infants to prevent AD progression and food allergy
NCT04706559	N/A	Completed	98	Probiotic supplementation effect on SCORAD index in children with AD; disease-area evidence only, no fluticasone arm
NCT00616538	Phase 4	Completed	121	Non-steroidal barrier device (EpiCeram) vs mid-strength fluticasone propionate 0.05% in pediatric AD
NCT00119158	Phase 4	Completed	90	Combination of pimecrolimus 1% + fluticasone (Cutivate) 0.05% vs vehicle in severe AD lesions
NCT01915914	Phase 4	Completed	107	Intermittent fluticasone propionate 0.05% cream (twice weekly) + moisturizer vs standard care to reduce relapse in stabilized pediatric AD
NCT01772056	Phase 3	Terminated	54	Twice-weekly fluticasone propionate maintenance cream to reduce relapse risk in mild/moderate pediatric AD; trial terminated early
NCT00546000	Phase 4	Completed	56	Open-label study of fluticasone propionate (Cutivate) lotion effects on HPA axis in pediatric AD
NCT03594565	Early Phase 1	Completed	13	Small case series on topical nasal steroids for skin reactions to glucose monitoring devices in youth with T1DM; different disease context

Literature Evidence

PMID	Year	Type	Journal	Key Findings
19571596	2009	Review	Neuroimmunomodulation	Reviews HPA-axis suppression risk with intranasal corticosteroids across allergic rhinitis, asthma and atopic dermatitis; a general safety-class review, not furoate/AD-specific efficacy data
40066386	2025	Case Report	Indian J Otolaryngol Head Neck Surg	Case report on allergen immunotherapy in a patient with autoimmune disease and atopic dermatitis comorbidity; not a fluticasone efficacy study

South Africa Market Information

Fluticasone furoate has no current SAHPRA registrations on file (0 licenses) and is recorded as Not Marketed in South Africa.

Safety Considerations

Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.

Note: Detailed warnings/contraindications (TFDA/PI label data) and full mechanism-of-action data are flagged as outstanding data gaps in this evidence pack and are required before a formal safety assessment (S1) can proceed.

Conclusion and Next Steps

Decision: Hold (Research Question stage)

Rationale: Evidence specific to fluticasone furoate in atopic eczema is indirect — nearly all retrieved trials use the propionate ester as the active drug/comparator, and the two available publications are a general ICS safety review and an unrelated case report. Combined with zero current SAHPRA registration, there is not yet a marketed formulation or ester-specific efficacy dataset to support progression beyond a research question.

To proceed, the following is needed:

Direct trial or comparative data for fluticasone furoate (not propionate) specifically in atopic dermatitis/eczema
SAHPRA registration status and Professional Information, since the product is not currently marketed in South Africa
Mechanism-of-action and PI warnings/contraindications data (currently listed as blocking/high-severity data gaps: DG001, DG002)
A formal assessment of pharmacological similarity between the drug’s established indications (allergic rhinitis/asthma) and atopic eczema
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.